Clinical Trial

The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the accuracy of the Cambridge Medical Technologies, LLC second generation (2nd Gen) LabPatch glucose sensing system compared to a laboratory glucose analyzer (YSI 2300 STAT Plus) and 2 commercial glucometers, OneTouch Verio and Freestyle Lite. The primary endpoint of this study is the mean absolute relative difference (MARD) for 2nd Gen LabPatch system compared to each of the above mentioned glucose references over a 6 hour outpatient visit.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-02-22; most recent amendment 2026-05-27.
Status change: Recruiting → Active, Not Recruiting 2026-05-27
Trial Details
NCT Number NCT05754281
Lead Sponsor Joslin Diabetes Center
Collaborators: Cambridge Medical Technologies, LLC
Conditions Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Enrollment 60 participants
Start Date 2023-02-03
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-29